Boehringer sales rise as Jardiance and Ofev thrive
admin 1st August 2018 Uncategorised 0Prescription drug sales were $7.1 billion for the first half of the year More: Boehringer sales rise as Jardiance and Ofev thrive Source: News
read more
Prescription drug sales were $7.1 billion for the first half of the year More: Boehringer sales rise as Jardiance and Ofev thrive Source: News
read moreEliquis, Ibrance, Xeljanz and biosimilars help drive profit growth More: Biosimilars and key brands drive Pfizer to raise forecasts Source: News
read moreHere is some other vaccine news of note for the week. More: News of Note—Pfizer, Sanofi Pasteur and more Source: fierce
read morePfizer’s new three-unit structure may be all about driving growth for now. But don’t count out a long-awaited generics divestment down the line. That’s the message executives had for investors Tuesday as they clarified the reasoning behind Pfizer’s latest reorganization.
read moreWith an ambition to expand its position as a leading dermatology company, Leo Pharma has agreed to acquire Bayer’s prescription dermatology business, which delivered €280 million ($328 million) in 2017 sales. More: Bayer to sell prescription dermatology unit and transfer
read moreAs much as Sanofi has struggled with diabetes and generic drugs the past few years, it could typically count on vaccines and Genzyme to come to the rescue. This quarter, Genzyme played its usual lifeguard role, but vaccines fell down
read more© 1994 - 2026 B.M. Pharmaceuticals